Clear Street Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $116
Clear Street has reiterated its Buy rating for Protagonist Therapeutics (PTGX.US) and increased its target price to $116. This adjustment reflects a positive outlook on the company's financial prospects and market position.
Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NASDAQ
This article provides live stock quotes and charts for Protagonist Therapeutics Inc. (PTGX). It shows the current stock price, recent performance, and indicates that there is insufficient data for analyst ratings or earnings information. The content is presented within the context of a trading platform, offering tools and resources related to stock trading.
PTGX SEC Filings - Protagonist Ther 10-K, 10-Q, 8-K Forms
This page provides access to Protagonist Therapeutics (PTGX) SEC filings, including 10-K, 10-Q, 8-K reports, and insider trading forms, aggregated by Stock Titan. It details the types of information found in these filings, such as financial results, corporate updates, clinical milestones, and governance matters. The platform enhances accessibility with AI-powered summaries and real-time updates from EDGAR to help investors interpret regulatory disclosures.
Jefferies Maintains Buy on Protagonist Therapeutics (PTGX) PT $121 Mar 2026
Jefferies and Johnson Rice both maintained a Buy rating on Protagonist Therapeutics (PTGX) on March 18, 2026. Jefferies raised its price target to $121, while Johnson Rice highlighted a Truist model projecting $730 million in peak Icotyde royalties. These actions signal analyst confidence in the company's revenue pathways, leading to a reported stock price increase of around 6% following the announcements.
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock?
Protagonist Therapeutics (PTGX) stock rose 4.7% in a recent trading session, closing at $30.85, outperforming the S&P 500's daily gain. While the company's Q4 earnings call is anticipated to provide further direction, investors are keen to see if this momentum can be sustained, especially given recent positive revisions to earnings estimates for the upcoming quarter.
Protagonist Therapeutics (NASDAQ:PTGX) Surges To New High Amid Nasdaq Today Focus
Protagonist Therapeutics (NASDAQ:PTGX) is experiencing significant price movement and institutional activity, solidifying its position in the biotech sector amidst current Nasdaq trends. The company's trading performance is influenced by sector sentiment and clinical developments, relying on its research, clinical trials, and peptide technology to innovate immune-based treatments.
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High - What's Next?
Protagonist Therapeutics (NASDAQ:PTGX) recently hit a new 52-week high of $105.99 on heavy trading volume. Despite this momentum and a "Moderate Buy" consensus from analysts with a target of $107.31, the company reported an earnings miss and significant insider selling, including shares from the CEO and CFO. The article notes hedge funds and institutional investors have also adjusted their positions in PTGX.
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock?
Protagonist Therapeutics (PTGX) stock rose 4.7% in a recent trading session, closing at $29.13. This increase was driven by investor optimism following positive analyst recommendations and clinical trial updates for its lead drug, rusfertide. The article discusses whether this upward momentum is sustainable given the company's fundamentals and market sentiment.
Protagonist Therapeutics stock hits all-time high at 105.71 USD By Investing.com
Protagonist Therapeutics (PTGX) stock has reached an all-time high of $105.71, currently trading at $105.99, demonstrating a 125.11% increase over the past year. Analysts predict profitability this year with earnings of $3.78 per share, despite the stock appearing overvalued. Recent FDA approval for its psoriasis drug, Icotyde, has further boosted investor confidence and led to multiple analyst price target increases.
How Protagonist Therapeutics Inc. (PTGX) Affects Rotational Strategy Timing
The article analyzes Protagonist Therapeutics Inc. (PTGX) stock, identifying strong sentiment across all horizons and an exceptional risk-reward short setup. It details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide traders on optimal entry and exit points. The report suggests an overweight bias due to strong signals and provides key support and resistance levels.
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following ICOTYDE’s Phase 3 Psoriasis Data Release - Learn Why
Protagonist Therapeutics (PTGX) has released positive one-year Phase 3 data for its oral drug ICOTYDE (icotrokinra) for moderate to severe plaque psoriasis, highlighting its potential as an alternative to injectables and the strength of its peptide discovery platform. This data, along with ICOTYDE's recent FDA approval and rusfertide's priority review, shifts the company's focus from clinical milestones to commercial execution, raising new questions about pricing, market access, and real-world safety. Investors should now consider these commercialization risks, potential future dilution, and the company's valuation, especially given its strong stock performance and continuing losses.
Protagonist Therapeutics Insider Sold Shares Worth $2,581,504, According to a Recent SEC Filing
An insider at Protagonist Therapeutics sold shares valued at $2,581,504, according to a recent SEC filing. The company is a biopharmaceutical firm developing peptide-based treatments for hematological and inflammatory diseases, with key assets like rusfertide and JNJ-2113. This sale follows other recent insider transactions and news regarding FDA approvals and price target increases from analysts.
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Protagonist Therapeutics, Inc. announced the presentation of one-year Phase 3 data for ICOTYDE (icotrokinra) at the 2026 American Academy of Dermatology Annual Meeting. The data reinforces ICOTYDE's potential as a differentiated oral therapy for moderate-to-severe plaque psoriasis, demonstrating lasting skin clearance and a favorable safety profile as a once-daily pill. This oral peptide specifically blocks the IL-23 receptor and is being developed and commercialized in collaboration with Johnson & Johnson.
Protagonist Therapeutics (PTGX) price target increased by 11.65% to 114.50
Protagonist Therapeutics (PTGX) has seen its price target increased by 11.65% to $114.50. This adjustment reflects an updated valuation for the company's stock by analysts. Investors may consider this an indication of positive sentiment regarding future performance.
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 24,000 Shares of Stock
Protagonist Therapeutics (NASDAQ:PTGX) Director Harold Selick sold 24,000 shares of the company's stock on March 26th for a total of $2.52 million, reducing his stake by 28.29%. This sale occurred despite analysts maintaining a "Moderate Buy" rating with a consensus price target of $107.31, even after the company missed quarterly EPS and revenue estimates. The stock is currently trading near its 1-year high, with institutional investors owning a significant portion of its shares.
Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells $2,581,503.60 in Stock
Protagonist Therapeutics' CFO, Asif Ali, sold 24,765 shares of PTGX stock worth $2.58 million on March 26th, reducing his stake by nearly 29%. This follows earlier sales in January totaling approximately $4.55 million, indicating significant insider selling. Despite the insider sales and missed quarterly earnings expectations, analysts maintain a "Moderate Buy" consensus with an average target price of $107.31.
Protagonist Therapeutics Insiders Sold Shares Worth Over $6.7M
Insiders at Protagonist Therapeutics (PTGX) recently sold shares totaling over $6.7 million. The sales involved Chief Financial Officer Ali Asif, Director Harold E. Selick, and Chief Medical Officer Arturo Molina MD. Each executive sold a significant number of shares at prices ranging from approximately $104-$105 per share, as detailed in recent SEC filings.
Protagonist Therapeutics director Selick sells $2.52 million in shares
Protagonist Therapeutics director Harold E. Selick sold 24,000 shares of common stock for $2.52 million after exercising options. The stock sale occurred near its 52-week high, with the company recently receiving FDA approval for its drug Icotyde, leading to increased price targets from several analysts. Following these transactions, Selick directly owns 60,845 shares.
[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity
Protagonist Therapeutics, Inc.'s CFO, Asif Ali, engaged in insider trading activity by exercising stock options and simultaneously selling shares. He acquired 24,765 shares through options at exercise prices of $19.19 and $12.17, then sold all 24,765 shares in open-market transactions at a weighted average price of $104.24 per share. After these transactions, Ali directly owned 60,753 common shares, including those from an employee stock purchase plan.
Vanguard disaggregates holdings; Protagonist Therapeutics (NASDAQ: PTGX) shows 0% ownership
Vanguard has amended its Schedule 13G/A filing for Protagonist Therapeutics (PTGX), reporting 0% beneficial ownership. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report holdings separately. The filing clarifies that Vanguard itself no longer beneficially owns these securities, relying on SEC Release No. 34-39538 for disaggregated reporting.
Protagonist Therapeutics PTGX: Ali Asif sells $2.58 million in stock
Protagonist Therapeutics CFO Ali Asif sold 24,765 shares of common stock for $2.58 million on March 26, 2026, after exercising options to acquire the same number of shares. This transaction occurred shortly after the FDA approved the company's psoriasis treatment, Icotyde, leading several analysts to raise their price targets for Protagonist Therapeutics. The stock has seen a 100% return over the past year, though InvestingPro analysis suggests it may be overvalued.
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After A 107% One-Year Surge?
Protagonist Therapeutics (PTGX) has seen a 107% surge over the last year, leading investors to question its current valuation. A Discounted Cash Flow (DCF) analysis by Simply Wall St suggests the stock, trading at around US$102, is significantly undervalued at $368.91 per share, implying a 72.3% undervaluation. While its P/B ratio of 10.61x is above the industry average, the DCF model indicates substantial upside potential based on projected future cash flows.
Asif Ali sells 54,791 PTGX shares; planned 24,765‑share option sale (PTGX)
A Form 144 filing for Protagonist Therapeutics (PTGX) indicates that Asif Ali completed two sales totaling 54,791 shares in January 2026, generating over $4.5 million. Additionally, the filing outlines a planned stock option exercise for 24,765 shares set for March 26, 2026. The company's shares outstanding are reported as 63,808,716 as of the same date.
[144] Protagonist Therapeutics, I... | PTGX SEC Filing - Form 144
Protagonist Therapeutics, Inc. (PTGX) has filed a Form 144 with the SEC, indicating a proposed sale of 24,000 shares of common stock with an aggregate market value of $2,520,000. These securities were acquired on March 26, 2026, through a stock option exercise and are intended to be sold on NASDAQ. The filing is categorized as neutral in both impact and sentiment.
PTGX (NASDAQ: PTGX) insider files Form 144 to sell 15,000 shares
Protagonist Therapeutics (NASDAQ: PTGX) has had an insider file a Form 144 to sell 15,000 shares through a stock option exercise, with cash settlement planned for March 26, 2026. The filing indicates previous open-market dispositions by the same individual, Arturo Molina, in January 2026. This is a routine Rule 144 notice of intended resale and prior dispositions.
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's What Happened
Protagonist Therapeutics (NASDAQ:PTGX) recently reached a new 52-week high of $105.69, despite reporting weak fundamentals including an EPS miss and lower-than-expected revenue. Analysts maintain a "Moderate Buy" consensus with an average target price of $107.31, and institutional investors hold a significant portion of the stock, even as insiders have sold shares. The company, a clinical-stage biopharmaceutical firm, focuses on developing orally administered peptide-based therapies for immune-mediated and other serious diseases.
Protagonist Therapeutics Insider Sold Shares Worth $5,524,700, According to a Recent SEC Filing
An insider at Protagonist Therapeutics sold shares valued at $5,524,700, as disclosed in a recent SEC filing. The biopharmaceutical company focuses on developing peptide-based treatments for hematology, blood disorders, and inflammatory diseases. This transaction follows other recent news for the company, including regulatory approvals for some of its pipeline drugs and analyst target price adjustments.
Dinesh Ph Patel Sells 54,641 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock
Protagonist Therapeutics CEO Dinesh Ph Patel sold 54,641 shares of the company's stock on March 25th, valued at over $5.5 million. This transaction reduced his stake by 9.43% to 524,938 shares. Despite the insider selling and a recent earnings miss, Wall Street analysts maintain a "Moderate Buy" rating for PTGX with an average target price of $107.31.
Protagonist Therapeutics(PTGX.US) Officer Sells US$5.52 Million in Common Stock
Protagonist Therapeutics (PTGX.US) officer, Dinesh V. Patel, sold 200,000 shares of common stock on March 22, 2024, for a total value of $5.52 million. This transaction was disclosed in a Form 4 filing with the SEC.
Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) March 2026
Jefferies and Johnson Rice both reaffirmed a Buy rating on Protagonist Therapeutics (PTGX) on March 18, 2026. Jefferies also raised its price target to $121, while Johnson Rice cited $730M peak Icotyde royalties in its modeling. These actions signal continued analyst confidence in the company's late-stage assets and commercialization potential, leading to a 6.7% intraday stock movement.
PTGX (NASDAQ: PTGX) option exercise sale of 54,700 shares
Protagonist Therapeutics (NASDAQ: PTGX) has filed a Form 144, indicating a proposed sale of 54,700 shares of common stock through an option exercise on March 24, 2026, with cash proceeds. The filing also documents previous open-market dispositions by Dinesh Patel in January 2026. This regulatory notice informs the SEC of the intended resale, satisfying conditions for certain resale thresholds and holding periods.
Why Protagonist Therapeutics (PTGX) Is Up 7.0% After First FDA Approval For ICOTYDE Psoriasis Drug
Protagonist Therapeutics (PTGX) saw its shares rise 7.0% following the U.S. FDA approval of ICOTYDE (icotrokinra) for moderate to severe plaque psoriasis. This approval marks a significant milestone, shifting the company's investment narrative from promise to commercial execution, though it also introduces pressure to perform in a competitive market while still operating at a loss. Investors are now focused on ICOTYDE's launch metrics and the upcoming rusfertide decision in Q3 2026 as key catalysts, amidst concerns about a rich valuation, ongoing net losses, and insider selling.
Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics
Wall Street analysts are optimistic about Protagonist Therapeutics following the FDA approval of Icotyde, a psoriasis drug co-discovered with Johnson & Johnson. The approval triggers a $50 million milestone payment to Protagonist, with eligibility for up to $580 million in additional payments and royalties. Analysts believe the drug will create significant value for Protagonist due to its strong efficacy and an earlier-than-expected approval.
A Look At Protagonist Therapeutics (PTGX) Valuation After ICOTYDE Receives U.S. FDA Approval
Protagonist Therapeutics (PTGX) has received U.S. FDA approval for its drug ICOTYDE, leading to increased attention on its commercial potential. Despite a strong stock performance and a high price-to-book ratio of 10.6x, indicating a rich valuation compared to the industry, Simply Wall St's Discounted Cash Flow model suggests the shares may be significantly undervalued. The article highlights the importance of individual research due to mixed signals regarding valuation, risks, and rewards.
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
Protagonist Therapeutics (PTGX) saw its stock rally by nearly 7% following FDA approval of its co-developed drug, icotrokinra (marketed as Icotyde), for moderate-to-severe plaque psoriasis. Partnered with Johnson & Johnson (JNJ), this approval triggered a $50 million milestone payment to Protagonist, with eligibility for up to an additional $580 million and tiered royalties. Icotyde is a significant oral treatment option, and its approval was backed by robust data from phase III studies, positioning it as a potential disruptor in the psoriasis market.
Protagonist Therapeutics (PTGX) Jumps 4.7%: Does the Stock Have More Room to Grow?
Protagonist Therapeutics (PTGX) saw its stock jump 4.7% after the FDA approved Johnson & Johnson’s icotrokinra, a therapy co-developed with Protagonist, for plaque psoriasis. While the company is projected to report a significant quarterly loss and revenue decline, analysts have raised their consensus earnings per share estimate, leading to a Zacks Rank #3 (Hold) rating. Investors are watching if the recent momentum continues for PTGX, especially given the positive earnings estimate revisions.
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) shares increased by 4.7% following the FDA approval of its partner Johnson & Johnson's icotrokinra (marketed as Icotyde) for plaque psoriasis. The stock's jump is also supported by a positive trend in earnings estimate revisions, with the consensus EPS estimate for the quarter revised 10.7% higher over the last 30 days. Analysts suggest investors watch PTGX for continued strength, noting its Zacks Rank #3 (Hold).
Protagonist Therapeutics (PTGX) Sees Target Price Upgrade from B
Barclays has reiterated its "Overweight" rating for Protagonist Therapeutics (PTGX) and increased its price target from $113.00 to $119.00, signaling continued confidence in the stock. This follows a trend of positive analyst actions, with other firms like Goldman Sachs, Citizens, TD Cowen, and Jefferies also recently raising their price targets. Wall Street analysts project an average target price of $112.25 for PTGX, with a consensus "Outperform" rating, while GuruFocus estimates a one-year fair value of $103.46.
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) saw its stock price jump 4.7% due to FDA approval of its partner Johnson & Johnson’s drug, icotrokinra (marketed as Icotyde), for plaque psoriasis. The drug is also being evaluated for other indications like psoriatic arthritis and Crohn's disease. Analysts expect a significant year-over-year decrease in both earnings and revenue for PTGX's upcoming report, but positive revisions to earnings estimates suggest potential for further stock appreciation.
A Look At Protagonist Therapeutics (PTGX) Valuation After ICOTYDE Receives U.S. FDA Approval
Protagonist Therapeutics (PTGX) recently received U.S. FDA approval for ICOTYDE, leading to increased attention on its commercial potential. Despite a significant share price increase over the last year, the company's valuation presents mixed signals. While its Price-to-Book ratio of 10.6x suggests overvaluation compared to the industry, a Discounted Cash Flow (DCF) model indicates the shares might be undervalued at their current price of US$101.68, with a fair value estimated around $366.87 per share.
Protagonist Therapeutics (PTGX) Receives Rating Update from JP Morgan
JP Morgan has maintained an "Overweight" rating for Protagonist Therapeutics (PTGX) and increased its price target from $95 to $106, an 11.58% rise. This update follows several other analysts who have also recently raised their price targets for PTGX. The average target price from 12 analysts is $112.25, indicating an "Outperform" status, with a potential upside of 9.73% from its current price.
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 4.6% Following Analyst Upgrade
Protagonist Therapeutics (NASDAQ:PTGX) saw its stock price rise by 4.6% following an analyst upgrade from Citigroup, which raised its price target to $125. This positive sentiment was reinforced by the FDA approval of ICOTYDE, triggering a $50 million milestone payment and significant future royalties for Protagonist, validating its oral-peptide approach. Despite the optimistic outlook and institutional endorsements, risks remain, including recent insider stock sales, missed EPS and revenue estimates, and the company's reliance on milestone and royalty payments rather than current product revenue.
Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) Mar 2026
Jefferies and Johnson Rice have re-affirmed their "Buy" ratings for Protagonist Therapeutics (PTGX) on March 18, 2026. Jefferies increased its price target for PTGX to $121, while Johnson Rice highlighted Truist's projection of $730 million in peak royalty revenue for Icotyde. These actions signify continued analyst confidence in Protagonist Therapeutics' potential, despite a modest negative intraday market reaction.
Barclays raises Protagonist Therapeutics stock price target on FDA approval
Barclays has raised its price target for Protagonist Therapeutics Inc. (NASDAQ:PTGX) to $119 from $113, maintaining an Overweight rating, following the FDA approval of Icotyde for psoriasis. Other analysts, including Jefferies, Citizens, Truist Securities, and H.C. Wainwright, have also increased their price targets, reflecting strong confidence in the company's future prospects and commercialization efforts with Johnson & Johnson. The company is in a strong financial position, eligible for significant royalties and milestones from Icotyde sales, and is also progressing with another drug, rusfertide.
FDA approves Protagonist Therapeutics ICOTYDE for psoriasis
Protagonist Therapeutics (NASDAQ:PTGX) has received FDA approval for its drug ICOTYDE (icotrokinra) to treat moderate-to-severe plaque psoriasis in adults and pediatric patients. This approval, based on strong Phase 3 clinical data, is a significant win for their oral peptide technology. Johnson & Johnson (NYSE:JNJ) will commercialize the drug, triggering an initial $50 million milestone payment to Protagonist, with eligibility for further milestones and tiered royalties.
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
Protagonist Therapeutics announced FDA approval for its oral IL-23 psoriasis pill, ICOTYDE (icotrokinra), for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older. This approval triggers a $50 million milestone payment from Johnson & Johnson, which will commercialize the drug, with Protagonist also eligible for tiered royalties and additional milestone payments. The approval was based on positive results from four Phase 3 studies involving 2,500 patients, demonstrating high efficacy and a favorable safety profile for the once-daily oral peptide.
Protagonist Therapeutics stock hits all-time high at 98.65 USD
Protagonist Therapeutics Inc. (PTGX) stock has reached an all-time high of $98.65, currently trading at $98.24 with a market capitalization of $6.2 billion, reflecting a significant 77.93% appreciation over the past year. Analyst consensus rates the stock a "strong buy" at 1.42, driven by advancements in its therapeutic pipeline and strategic partnerships. While InvestingPro indicates the stock might be overvalued, recent analyst reports from Citizens, H.C. Wainwright, JPMorgan, and Truist Securities have raised price targets, citing upcoming drug approvals and regulatory reviews as key catalysts.
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's Why
Protagonist Therapeutics (NASDAQ:PTGX) recently hit a new 52-week high of $99.31, with a market capitalization of $6.24 billion, despite missing quarterly EPS and revenue estimates. Analysts have largely maintained "Buy" ratings and increased price targets, with an average target of $101.08. Insider selling of approximately $16.9 million in stock over the last three months contrasts with high institutional ownership of 98.63%.
Protagonist Therapeutics, Inc. $PTGX Holdings Boosted by HighVista Strategies LLC
HighVista Strategies LLC significantly increased its holdings in Protagonist Therapeutics (NASDAQ:PTGX) by 110.3% in the third quarter, making it their sixth-largest position. Despite this institutional confidence and a "Moderate Buy" analyst consensus with a target price of $101.08, Protagonist Therapeutics missed its quarterly earnings and revenue estimates, and insiders have sold off a substantial number of shares. The company, a clinical-stage biopharmaceutical firm, focuses on developing orally administered peptide-based therapies for immune-mediated diseases.
Farallon Capital Management LLC Acquires 24,000 Shares of Protagonist Therapeutics, Inc. $PTGX
Farallon Capital Management LLC increased its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 0.4%, purchasing an additional 24,000 shares to own a total of 6,196,006 shares, making it their 17th largest position. Despite this institutional accumulation, Protagonist Therapeutics reported a weak quarter, missing earnings and revenue estimates, and analysts maintain a "Moderate Buy" rating with a consensus price target of $101.08. Insiders have sold a significant number of shares recently, highlighting mixed sentiment surrounding the company.
